GWP4202541

**GWP4202541** is an investigational, orally administered complex botanical drug product originally developed by GW Pharmaceuticals for behavioral and psychological symptoms in dementia. It contains cannabinoids including cannabidiol and delta-9-tetrahydrocannabinol together with non-cannabinoid plant-derived constituents. Its pharmacology is not fully characterized as a single target mechanism because it is a chemically heterogeneous botanical mixture. A first-in-human Phase I study evaluated single- and multiple-dose oral administration, safety, tolerability, and pharmacokinetics in healthy adult and older adult participants. ([hra.nhs.uk](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/fih-clinical-trial-testing-gwp4202541-in-healthy-volunteers/))